




## clinical study of LucRo<sup>®</sup> – shoes

### Contents:

- Author/Abbreviations
- Abstract
- Introduction
- Study design/Patients and methods
- Statistics
- Results
- Definitions
- Table
- Figures 1-3
- References



Schein Shoe Service  
Postfach 11 06 09  
D-42866 Remscheid  
Germany



Tel. +49(0)2191/910-201  
Fax. +49(0)2191/910-102  
E-mail: shoe-service@schein.de  
www.schein-shoe-service.de

### **Der direkte Draht zum schein shoe service:**

**Tel. 0 21 91/910 - 201**

**Fax 0 21 91/910 - 102**

**Geschäftszeiten:**

Montag - Donnerstag 7.30 - 18.45 Uhr  
Freitag 7.30 - 16.00 Uhr

Effectiveness of a new brand of stock „diabetic“ shoes to protect against diabetic foot ulcer relapse. A prospective cohort study.

K.Busch, E.Chantelau

Diabetes-Fussambulanz, MNR-Klinik der Heinrich-Heine-Universität Düsseldorf.

Abbreviations: ICD-10 nr. =International classification of diseases, 10<sup>th</sup> Version(in German).

SDS= stock „diabetic“ shoes. EURO= European currency; 1 EURO is approximately 0.7

English Pound, or 1 US Dollar. EVA= ethylene-vinyl-acetate. PIVD= peripheral ischaemic

vessel disease. PNP= polyneuropathy

**Address for correspondence:**

**Prof.Chantelau**

**Diabetes-Fussambulanz MNR-Klinik**

**Heinrich-Heine-Universität Düsseldorf**

**Postfach 10 10 07**

**D-40001 Düsseldorf**

**Fax +49-211-811-8772**

## Summary

**Aims:** Diabetic patients with podopathy (diabetic foot syndrome) may need protective footwear, be it customised or industrially produced stock „diabetic“ shoes (SDS). The effectiveness of each type of „diabetic“ shoe needs to be proven clinically, e.g. in terms of prevention of foot ulceration. The following study assesses a new German SDS, the LucRo® shoe, which consists of rocker-shaped walking sole, a standardised shock absorption insole, and soft uppers without stiff toe-caps. The LucRo® SDS has been registered as a Medicinal Product according to the European Community Guideline 93/42/EC.

**Methods and patients:** A total of 92 high-risk diabetic patients (mean age of 63 years, and a duration of diabetes of 13 years) with healed foot ulcer were recruited prospectively over 31 months; 87 patients suffered from polyneuropathy, 24 patients had peripheral ischaemic vessel disease. One group of patients (n=60) received the LucRo® SDS and wore them, while the remaining patients (n=32) did not receive the SDS and were forced to use their normal footwear. This allocation reflects the haphazard reimbursement policies of the individual patients' health insurances, and is in accordance with the current German legislation. The patients were followed-up for up to 42 months until the first foot ulcer relapse, or the end of the study.

**Results:** There were no differences between the groups concerning age, sex, type and duration of diabetes, prevalence of polyneuropathy and peripheral ischaemic vessel disease, frequency of foot care and mortality rate. The first year annual rate of foot ulcer relapses was significantly different between the groups: 60% without SDS versus 15 % with SDS. The overall cumulative ulcer-free survival was significantly greater with SDS ( $p < 0.0001$ , log rank test).

**Conclusion:** The LucRo® stock „diabetic“ shoe has shown to be highly effective in the prevention of foot re-ulceration in high-risk patients with diabetic podopathy.

**Key words:** amputation, diabetic foot, diabetes, complications, foot ulcer, neuropathy, shoes, footwear

## Introduction

Footwear significantly affects the course of the diabetic foot syndrome (diabetic podopathy). If unsuitable, footwear injures the feet, thereby increasing the risk of amputation in patients with loss of protective sensation. If appropriate, footwear can protect the feet from such lesions. Mismatch between foot and shoe, and „normal“ shoe design or materials are causally involved in nearly 80% of all foot lesions that precede amputations in diabetic patients (1). Empirical criteria for the making of special „diabetic“ protective footwear have already been devised sometime ago (2). However, intervention studies with diabetic footwear are rare, and the proof of its efficacy in terms of clinical endpoints, e.g. prevention of foot ulceration, is still scarce (3). Clinical trials on „diabetic“ footwear in free-living patients are difficult to perform: some patients would reject them for cosmetic reasons, while others would wear them only temporarily (4,5). However, one of the main problems is the lack of standardisation of „diabetic“ footwear, and the lack of standardisation of the diabetic feet regarding size and shape(6). Previous reports have claimed clinical benefits for some stock „diabetic“ shoes, however, there were limitations within the methodology utilised(5,7-9). Due to the fact that to date there is no unequivocal clinical proof as to the effectiveness of „diabetic“ stock shoes, the German health insurance companies generally do not cover the costs of SDS prescription, whereas they are legally obliged to reimburse any kind of prescribed medication. However, on demand some of the approximately 500 various local, regional, and industry-based health insurances would reimburse approximately 170 EURO for each pair of „diabetic“ stock shoes, which is about 2/3 of the total costs. It is not publicly known, which insurances do or do not reimburse the costs for „diabetic“ stock shoes; and likewise, neither have the insurances followed their reimbursement policies consistently over time. Thus, the attitude of German health insurances as to the reimbursement of SDS continues to be unpredictable, and the approval or decline of reimbursement is purely haphazard. The rate of foot ulcers can be appreciably high (58-100% per year) in unprotected high-risk patients with a history of diabetic foot lesions(9,10). Treatment with

protective footwear can lower this rate considerably (3,9,11,12), which makes a randomised, placebo-controlled trial with an unprotected control group of high-risk patients problematic. The following study was therefore conducted with a cohort of health insurance beneficiaries, to whom their insurance companies –by chance- either provided or withheld stock „diabetic“ shoes by covering or not the costs.

#### Study design, patients, materials and methods

\*Study design: The study was single centered, prospective cohort study , using health insurance based data, and practice registry and case notes. The study assessed the effects of a particular stock „diabetic“ shoe on the rate of foot ulcer relapses in patients with diabetic podopathy. Approval from the local ethics committee was obtained.

\*Patients: The patients included in the study all belonged to a large practice of two internists specialising in diabetology. The practice is located in an industrial city in western Germany (approx. 600 000 inhabitants), and is caring for about about 2000 patients with diabetes.

The patients were selected from the practice's patients registry according to the following criteria: they had to be beneficiaries of a state-approved or private health insurance, had to have diabetes with complications (ICD-nr. 10.7(type-1 diabetes) or ICD-10 nr. 11.7(type-2 diabetes)), and had to have received treatment for a foot ulcer (according to the practice's application for reimbursement for wound care (general practitioners procedures' numbers 2002, or 2004, or 2020, or 2021 wound care)). The foot ulcer had to be healed completely by that practice(see below).The patients had to have polyneuropathy(PNP) and/or peripheral ischaemic vessel disease(PIVD); major foot deformations and limitations in mobility of foot joints had to be absent. A particular type of stock footwear(see below) had to be prescribed within 4 weeks after healing of the ulcer between June 1999 and June 2001; the patients had to remain attached to the practice until the end of the study 31.12.2001.

A total of 92 patients met the inclusion criteria and were followed for ulcer relapses. Their clinical characteristics are summarised in Table 1.

\*Definitions: PNP was diagnosed using the Rydel-Seiffer tuning fork(13 ); a vibration sensation < 5/8 at the first metatarsal head was taken indicative of PNP.

PIVD was diagnosed using a continuous wave 8 mHz Doppler device; an ankle/arm pressure index < 1.0 or an abnormal flow-profile suggestive of collateral circulation was taken as indicative of PIVD.

A foot ulcer was defined as any partial or complete disruption of the skin (Wagner stage 1-2), with or without inflammation. Healing of an ulcer was defined as complete closure of a lesion with durable skin, leading to the cessation of wound care.

\*Stock „diabetic“ shoes(SDS): To all study patients, the same brand of industrially made SDS was prescribed (LucRo®, Schein Orthopädie Service KG, Remscheid/Germany), which had basically the same design, but varied in colours and versions for men and women. Other particular features of the LucRo® shoes were as follows: three widths (small, medium, large); stiff, convex walking sole („rocker bottom“) from EVA and rubber (Softgummi®); very soft upper of three layers (from inner to outer: cloth, rubberfoam, leather) without any kind of toe cap; a shock-absorbing standardised, non-moulded insole comprising of three components (rear part 6 mm Lunasoft®, 42° Shore A hardness; anterior part 6mm Lunaflex®, 20° Shore A hardness, covered with 3 mm thick P<sup>2</sup>, 17° Shore A hardness). The outline of the anterior part of the insole is shaped less triangular, but more rectangular (Fig. 1), fitting reasonably to the dimensions of the feet of elderly persons (6), and corresponding with the shape devised by Helbig et al. on the basis of anthropometric measurements in healthy men(14). A picture of such a SDS is shown in Fig. 2. The softness of the upper- which is easily deformable, see Fig.2- is required to avoid toe pressure strain. The rocker-bottom decreases peak plantar pressures beneath the metatarsal heads and prolongs pain-free walking distance in cases of PIVD(15), and the insole acts by cushioning the planta pedis in the forefoot area (where most pressure strain occurs during walking). These items(3) had been recommended by Tovey (2) on empirical grounds. Furthermore, the LucRo® shoe was designed along earlier experiences with other brands of German SDS(5,8,11). When the LucRo® SDS came on the market in 1999, they represented the 3<sup>rd</sup> generation of German

SDS. The LucRo® SDS has been registered as an approved medicinal product class I, in confirmation with the European Community Guideline 93/42 EC.

By contrast to these SDS, normal fashion shoes (e.g. Oxford style) mostly have only one width which is too narrow for most diabetic feet(6), have a (stiff) toe cap , and hard insoles(3).

\*Allocation of stock „diabetic“ shoes(SDS): To all patients at least 1 pair of SDS was prescribed, provided the foot shape was suitable for the SDS at the shoe-fitting. The prescription was given to one single retailer (Innova-med Inc., Haan/Germany), who then by letter applied to the patients's insurance companies for reimbursement. In all cases, he as well as the patients received response letters of either approval or decline by their insurances. While 15 insurances (including Allgemeine Ortskrankenkasse and various Betriebskrankenkassen) of 60 patients approved reimbursement of approximately 2/3 of the total costs of approx. 250 EURO, 4 insurances (Deutsche Angestelltenkrankenkasse, Technikerkrankenkasse, Bundesknappschaft , Betriebskrankenkasse Hoesch) of 32 patients categorically declined to reimburse any part of the costs. The former 60 patients did receive the SDS from the retailer after having paid him for the rest (74 EURO), while the latter 32 did not receive the SDS; this was confirmed by cross-checking the data on file of the SDS retailer and the practice. If the patients were satisfied by the first pair of SDS, one or two more pairs were prescribed and the appropriate reimbursement received.

Statistics: Analyses were carried out using Kaplan-Meier life-table analysis, log-rank test, Kruskal-Wallis test and chi-square test. Medians are reported with interquartile ranges; 95% confidence intervals were calculated when appropriate.  $P < 0.05$  was considered statistically significant.

## Results

The patients were followed prospectively from the date of the prescription of SDS until ulcer relapse or end of the study 31.12.2001 for up to 42 months. During follow-up, 5 patients had

died, 1 patient with and 4 patients without ulcer relapse. The causes of death (coronary event, suicide, cancer) were unrelated to the diabetic podopathy. The patients differed in the ulcer relapse rates according to whether or not they had received SDS; otherwise, the patient characteristics were similar (Table 1). The 32 patients without SDS were followed until ulcer relapse or end of the study for a median (interquartile range) of 5 (2;19) months. In the first year of follow-up, 19 patients (60%(95% CI 43-77%)) had experienced an ulcer relapse, and 6 more patients in the remaining time. The 60 patients with SDS were followed for 19 (8;25) months. In the first year of follow-up, 9 patients (15%(95%CI 6-24%) had experienced an ulcer relapse, and 3 more patients in the remaining time ( $p<0.001$  versus patients without SDS). The absolute risk reduction by the SDS treatment in the first year was 45% (95% CI 26-64%) , and the number-needed-to-treat was 2.2 patient per year to prevent one foot ulcer relapse. The ulcer-free proportions of patients over time are depicted in Fig.3.

#### Comment

The present data confirm that stock „diabetic“ shoes (SDS) with a particular performance can significantly reduce the incidence of foot ulcer relapse in high-risk patients with diabetic podopathy (without foot deformity). The brand of SDS used in the present study , LucRo®, has shown similar treatment effects as another brand, Podiabetes by Buratto®, which is no longer on the market(9). The present study is one of the largest controlled trial on prescribed SDS, with a control group of high-risk patients forced to continue with their self-selected non-protective normal footwear. Although all German citizens are legally charged similar health insurance fees, and the insurances are legally obliged to reimburse for every medical prescription of state-approved medication and treatment irrespective of the patients' socio-economic status, the control patients were –by chance- denied SDS by their health insurance companies. As SDS to date have not been officially approved, the health insurances have the right to refuse to pay anything, or to generously reimburse 2/3 of the costs. Withholding reimbursement for SDS by the insurances means that patients do not get it as prescribed. As such inconsistencies unpredictably occur within as well as between the

various German health insurance companies, this situation provided an ideal allocation basis with very little potential for bias. This study design deemed even more appropriate as a randomised clinical trial with a placebo-group appeared to be unjustified (16,17), because of the notoriously poor performance of normal footwear in high-risk patients. Moreover, data material generated by health insurances is increasingly used for analyses of patient outcomes (18,19).

The study patients were apparently very satisfied with their SDS, as 95% of them applied for a second and a third pair. A high compliance rate, may, thus have contributed to the high effectiveness of the LucRo® shoe. Previous studies have shown a correlation between the effectiveness of protective „diabetic“ footwear and the length of time the patients were wearing the shoes (5,11). The present study, however, did not address in particular the length of time the SDS were worn.

As far as foot care is concerned, all patients were offered podiatry (trimming nails and cutting calluses) by the practice staff. However, it was left at the patients' discretion how often they would show up for podiatry. In the present study, patients of both groups exhibited roughly the same frequency of podiatry, and of visits to the practice in general (Table.1).

„Footwear has never commanded much attention among the medical profession and many doctors do not realize how prescribing comfortable shoes can transform their patients' lives“ (20). Footwear may be extremely cumbersome to study in clinical terms, because it may require prolonged use to show a result (21), might not be very effective (22), or it might decrease the patients' compliance(23). Therefore, many researcher have resorted to surrogate endpoints instead, e.g. to the reduction in plantar pressure by certain kinds of footwear(3,22,24), or to a formal evaluation (25). However, the results were not unequivocal (3,20,24), and controversies remain (26). Caution is, therefore, required when judging the potential benefits of some protective footwear for diabetic patients at-risk. The clinical proof of the effectiveness, e.g. by preventing foot lesions, remains the gold standard for the evaluation of „diabetic“ footwear. This holds true not only for SDS, but also for custom shoes (11) which, to our knowledge have never been studied rigorously in controlled trials.

Finally, it must be emphasised that the beneficial effects of LucRo® shoes have been obtained in high-risk patients with polyneuropathy and/or peripheral ischaemic vessel disease, who have an extremely high rate of spontaneous re-ulceration of up to 100% per year. It remains to be demonstrated, whether these shoes will also protect patients with spontaneous 7% annual ulcer incidence, which is the incidence rate in „low-risk“ diabetic patients without any prior foot ulceration (27). Previous studies with different types of special „diabetic“ footwear failed to demonstrate a significant reduction in foot ulcer rates in such „low-risk“ patients (28,29 30). In 240 low-risk patients without polyneuropathy using special footwear, Reiber et al.(30) have shown recently unchanged foot ulcer rates, while shoe-induced foot ulcer rate was reduced in 160 high-risk patients using special footwear with particular insoles (9 out of 47 ulcers), as compared to normal footwear (19 out of 37 ulcers) (31).

The prevention of re-ulceration in patients with diabetic podopathy is highly cost-effective, as foot ulceration increases the treatment costs per patient by 10.000 to 16.000 USDollars(32), while the costs for 3 pairs of SDS in our study were about 700 USDollars. Rangnarsen-Tennvall et al. have calculated that in high-risk patients a comprehensive prevention programme with regular podiatric care and SDS is cost-effective, if it reduces the foot ulcer incidence by at least 25% (33).

In conclusion, the present data indicate that a particular brand of stock „diabetic“ shoe, the LucRo® shoe, is effective in reducing the incidence of foot ulcer-relapses by 45% in the first year in high-risk diabetic patients with a polyneuropathy and /or ischaemic vessel disease and a history of foot ulceration. The unequivocal effectiveness of the SDS utilised in the present study (like another brand of SDS in a previous study (9)) warrants that future trials on „diabetic“ footwear in high-risk patients should be run as head-to-head comparisons (16,17), e.g. with a LucRo® shoe as reference, rather than as „placebo“-controlled trials.

**Conflict of interest statement:** E.Chantelau is a beneficiary of the health insurance Allgemeine Ortskrankenkasse; he has received honoraria for consulting the health insurances Bundesverband der Betriebskrankenkassen, Essen/Germany, and Allgemeine Ortskrankenkassen Bundesverband, Bonn/Germany. K. Busch has no conflict of interest.

Table 1	Stock „diabetic“ shoe (SDS)		p-value
	withheld*	provided*	
Patients with SDS prescription,n	32	60	
Gender (m/w),n	18/14	31/29	n.s.
Age,years	67(50;74)	62(54;73)	n.s.
Known duration of diabetes, yrs	15(6;23)	12(5;15)	n.s.
Length of follow-up, months §	5(2;19)	19(8;25)	<0.05
<u>Patients with</u>			
-Type-1 diabetes,n(%)	3(9%)	5(8%)	n.s.
-Type-2 diabetes,n(%)	29(91%)	55(92%)	n.s.
- PNP,n(%)	29(91%)	58(97%)	n.s.
- PIVD,n(%)	8(25%)	15(25%)	n.s.
- ulcer relapse,n(%)	25(78%)	12(20%)	<0.001
Visits to the practice per patient per month, n	1.0(0.6;1.5)	0.8(0.5;1.2)	n.s.
Foot care sessions, per patient per month, n	0.6(0.1;0.7)	0.5(0.1;0.6)	n.s.
Patients deceased during follow-up, n (%)	1(3%)	4(7%)	n.s.

\*due to withholding/providing reimbursement by individual patients' insurance companies.

Medians (interquartile range), or numbers(%), as indicated. n.s.= not significant. PNP= polyneuropathy; PIVD= peripheral ischaemic vessel disease; SDS= stock „diabetic“ shoe; § until ulcer relapse, death, or end of the study.

Fig. 1





Fig. 2



Fig. 3



Number  
at risk SDS  
no SDS

60	51	42	33	25	3
32	15	12	9	5	1

## References

- 1) Reiber GE: Who is at risk of limb loss and what to do about it? J Rehabil Res Dev 1994;31:357-362
- 2) Tovey FI. The manufacture of diabetic footwear. Diabetic Med 1984;1:69-71
- 3) Chantelau E. Footwear for the high-risk patient. In: AJM Boulton, H Connor, PR Cavanagh (eds) The Foot in Diabetes. 3<sup>rd</sup> Edition. 2000 John Wiley & Sons, Ltd. p131-142
- 4) Knowles EA, Boulton AJM. Do people with diabetes wear their prescribed footwear? Diabetic Med 1996;13:1064-1068
- 5) Striesow F. Konfektionierte Spezialschuhe zur Ulkusrezidivprophylaxe beim diabetischen Fussyndrom. (In German) Med. Klin. 1998;93:695-700
- 6) Chantelau E, Gede A. Foot dimensions in elderly people with and without diabetes mellitus- a databasis for shoe design. Gerontology 2002;48:241-244
- 7) Samanta A, Burden AC, Sharma A, Jones GR. A comparison between 'LSB' shoes and 'space' shoes in diabetic foot ulceration. Pract Diabet Int 1989;6:26
- 8) Baumann R. Industriell gefertigte Spezialschuhe für den diabetischen Fuss. (In German) Diab Stoffw 1996;5:107-112
- 9) Uccioli L, Faglia E, Monticone G, Favales F, Durolo L, Aldeghi A, Quarantiello A, Calia P, Menzinger G. Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care 1995;18:1376-1378
- 10) Tanudjaja T, Chantelau E. Recurrent neuropathic foot ulcer disease in diabetes mellitus. Abstract. Diabetologia 1996;39/Suppl.1:A 264
- 11) Chantelau E, Haage P: An audit of cushioned diabetic footwear.-relation to patient compliance. Diabetic Med 1994;11:114-116
- 12) Mueller MJ. Therapeutic footwear helps protect the diabetic foot. J Am Podiatr Med Assoc 1997;87:360-364
- 13) Boulton AJM, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabetic Med 1998;15:508-514
- 14) Helbig K, Jürgens HW, Pieper U. Anthropometrische Grundlagen für Sicherheitsschuhwerk für Männer. (in German). Forschungsbericht Nr. 268 der Bundesanstalt für Arbeitsschutz und Unfallforschung, Dortmund. Wirtschaftsverlag NW, Bremerhaven, 1981
- 15) Richardson JK. Rocker-soled shoes and walking distance in patients with calf claudication. Arch Phys Med Rehabil 1991;72:554-558
- 16) Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of a new treatment.I: ethical and scientific issues. Ann Intern Med 2000;133:455-463

- 17)Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of a new treatment.II:practical issues and specific cases. *Ann Intern Med* 2000;133:464-470
- 18)Sowell RD, Mangel WB, Kilczewski CJ, Normington JM. Effect of podiatric medical care on rates of lower-extremity amputation in a Medicare population. *J Am Podiatr Med Assoc* 1999;89:312-317
- 19)Sugarman JR, Reiber GE, Baumgardner G, Praela CM, Lowry J. Use of the therapeutic footwear benefit among diabetic Medicare beneficiaries in three states, 1995. *Diabetes Care* 1998;21:777-781
- 20)Ward AB. Footwear and orthoses for diabetic patients. Editorial. *Diabetic Med* 1993;10:497-498
- 21)Reiber GE, Smith DG, Boone DA, delAguila M, Borchers RE, Mathews D, Joseph AW, Burgess EM. Design and testing of the DVA/Seattle footwear system for diabetic patients with foot insensitivity. *J Rehabil Res Dev* 1997;34:1-8
- 22) Donaghue VM, Samow MR, Giurini JM, Chrzan JS, Habershaw GM, Veves A. Longitudinal in-shoe foot pressure relief achieved by specially designed footwear in high risk patients. *Diabetes Res Clin Pract* 1996;31:109-114
- 23)Woolridge J, Bergeron J, Thronton C. Preventing diabetic foot disease: lessons from the Medicare therapeutic shoe demonstration. *Am J Publ Health* 1996;86:935-938
- 24)Resch S, Apelqvist J, Stenström A, Aström I. Dynamic plantar pressure measurement in 49 patients with diabetic neuropathy with or without foot ulcers. *Foot and Ankle Surgery* 1997;3:165-174
- 25)Menz HB, Sherrington C. The footwear assessment form: a reliable tool to assess footwear characteristics of relevance to postural stability in older adults. *Clinical Rehabilitation* 2000;14:657-664
- 26)Ulbrecht JS, Perry J, Hewitt FG, Cavanagh PR. Controversies in footwear for the diabetic foot at risk. In: Kominski SJ(ed.) *Medical and surgical management of the diabetic foot*. St.Louis,MO: Mosby Year-book 1994; p 441-453
- 27)Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM. Multicenter study of the incidence and predictive risk factors for diabetic neuropathic foot ulceration. *Diabetes Care* 1998;21:1071-1075
- 28)Tyrrell W, Phillips C, Price P, Davies S, Gibby O. The role of orthotic therapy in minimising the risk of ulceration in the diabetic foot. Abstract. *Diabetologia* 1999;42/Suppl.1: A 308
- 29)Veitenhansl M, Hierl FX, Landgraf R. Ulcus- und Rezidivprophylaxe durch vorkonfektionierte Schuhe bei Diabetikern mit diabetischem Fußsyndrom: eine prospektive randomisierte Studie.Abstract.(in German). *Diabetes & Stoffwechsel* 2002;11(Suppl.1):106-107
- 30 Reiber GE, Smith DG, Wallace C, Sullivan K, Hayes S, Vath C, Maciejewski ML, Yu O, Heagerty PJ, LeMaster J. Effect of therapeutic footwear on foot reulceration in patients with diabetes. A randomized controlled trial. *JAMA* 2002;287:2552-2558

u E. Shoe-fitting, doesn't it really matter ? Letter. Gerontology 2002;48:

SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH.  
Outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care  
2001;24:2372-2387

son-Tennvall G, Apelqvist J. Prevention of diabetes-related foot ulcers  
simulations: a cost-utility analysis based on Markov model simulations.  
Diabetologia 2001;44:2077-2087